NCT06409949 MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
| NCT ID | NCT06409949 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Nebraska |
| Condition | Peripheral Arterial Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-06-01 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2023-06-01 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In our research, we are delving into whether taking MitoQ for six months can improve the symptoms and function of people diagnosed with peripheral artery disease, especially those who suffer from leg pain while walking, known as intermittent claudication. We will be checking if MitoQ helps people with claudication walk better, be more active every day, feel better about their lives, and if it enhances the health of their leg muscles.
Eligibility Criteria
Inclusion Criteria: 1. a positive history of chronic claudication 2. exercise-limiting claudication established by history and direct observation during a screening walking test administered by the evaluating vascular surgeon 3. documented lower extremity arterial occlusive disease based on ankle/brachial index measurements and/or arterial imaging 4. stable blood pressure, lipid and diabetes regimens and risk factor control for 6 weeks. Exclusion Criteria: 1. rest pain or tissue loss due to PAD (Fontaine stage III and IV) 2. acute lower extremity ischemic event 3. walking capacity significantly and primarily limited by conditions other than claudication including leg (joint/musculoskeletal, neurologic) and systemic (heart, lung disease) pathology.
Contact & Investigator
Iraklis Pipinos, MD
PRINCIPAL INVESTIGATOR
University of Nebraska
Frequently Asked Questions
Who can join the NCT06409949 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Peripheral Arterial Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06409949 currently recruiting?
Yes, NCT06409949 is actively recruiting participants. Contact the research team at Holly.DeSpiegelaere@va.gov for enrollment information.
Where is the NCT06409949 trial being conducted?
This trial is being conducted at Omaha, United States.
Who is sponsoring the NCT06409949 clinical trial?
NCT06409949 is sponsored by University of Nebraska. The principal investigator is Iraklis Pipinos, MD at University of Nebraska. The trial plans to enroll 60 participants.